J&J, AstraZeneca take Zytiga to Japan

Eric Palmer Noting that Japan is one of the world's fastest-growing pharmaceutical markets, Marc Dunoyer, AstraZeneca's executive vice president of global products and portfolio ...

AstraZeneca CEO celebrates 1st anniversary with promising lung cancer data

John Carroll The promising early results on AstraZeneca's lung cancer drug AZD9291 won't convince anyone that the troubled company is on the turnaround trail, but it's a ...

GSK, Sanofi, AstraZeneca ready to roll out premium-priced flu vaccines

Tracy Staton Will a new generation of flu shots pay off big for vaccine makers? We'll soon find out. As Reuters reports, several top drug companies are rolling out vaccines that ...

AstraZeneca Sued By University For Crestor Patent Infringement

esilverman Just a few short months after settling patent challenges to its all-important Crestor cholesterol-lowering pill, AstraZeneca is now facing a fresh lawsuit in which ...

Analysis: AstraZeneca revs up new deals in shift to late-stage R&D turnaround

John Carroll While explaining some fresh dents in earnings and revenue for the second quarter, AstraZeneca officials made it clear that they would continue to invest in new products–hitting ...

Celltrion’s manufacturing ops figure in AstraZeneca buyout buzz

John Carroll Rumors are swirling that AstraZeneca may have its sights set on the Korean biosimilars maker, and a buyout would give the British drugmaker–or any of its rivals–an ...

AstraZeneca reportedly eyeing deal for Korean biosim maker Celltrion

Carly Helfand Celltrion confirmed Wednesday that its largest shareholder is in discussions with financial adviser JPMorgan but stressed in a statement that "no definite structure, ...

Buzz: Hungry AstraZeneca circles a blockbuster biosimilars buyout

John Carroll Quoting sources close to the deal, Korea's Financial News says that Celltrion hooked AstraZeneca's interest after it began to cast around for a merger deal a few ...

AstraZeneca commits $815M to partner with FibroGen on anemia drug

John Carroll AstraZeneca CEO Pascal Soriot has taken another step forward in his turnaround campaign, committing $ 350 million in cash and up to $ 465 million in milestones to partner ...

Former AstraZeneca, MedImmune exec tapped to head Vivus

Alok Saboo FierceBiotech News

AstraZeneca, Bristol resubmit NDA for diabetes therapy dapagliflozin

Emily Mullin AstraZeneca and Bristol-Myers Squibb are trying once again to get U.S. approval for their drug dapagliflozin, an innovative but potentially risky treatment for Type 2 diabetes. FierceBiotech ...

Report: AstraZeneca, Pfizer, Novartis home in on Onyx bids

Tracy Staton AstraZeneca, Novartis and Pfizer are still in the hunt for Onyx Pharmaceuticals, Bloomberg's sources say. And Amgen, which triggered the whole bidding process with ...
Page 5 of 9« First...34567...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS